Status:
COMPLETED
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this real-world study is to understand the use of palbociclib as first treatment for Hormone receptor positive (HR+) and Human epidermal growth factor receptor 2 negative (HER2-) metast...
Eligibility Criteria
Inclusion
- Received at least one cycle of palbociclib as first line therapy for metastatic breast cancer between 01 January 2016 and 31 December 2022
- Histologically confirmed HR+/HER2- metastatic breast cancer
- Minimum of 3 months available follow-up on palbociclib
Exclusion
- Received a different CDK4/6 inhibitor before palbociclib in the first line
- Received other systemic therapy, including hormone therapy, 15-60 days prior to initiation of palbociclib
- Invalid or incomplete records (more specifically, complete duration of treatment on palbociclib, endocrine therapy or LHRH)
- Death date recorded on or before the date of index date
Key Trial Info
Start Date :
October 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 22 2024
Estimated Enrollment :
472 Patients enrolled
Trial Details
Trial ID
NCT06003114
Start Date
October 6 2023
End Date
February 22 2024
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alberta Health Services
Edmonton, Alberta, Canada, T5J 3E4